Comparison · NCT02220894-4b7e0064
Pembrolizumab vs Chemotherapy (SOC Treatment): Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Pembrolizumab vs Chemotherapy (SOC Treatment): Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE). Trial comparisons, record NCT02220894-4b7e0064. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02220894-4b7e0064
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.198 | 0.169 | 0.231 | wilson | |
| Risk in group 2 | 0.151 | 0.125 | 0.182 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0469 | 0.00474 | 0.0888 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.31 | 1.03 | 1.67 | log | |
| Odds ratio, group 1 over group 2 | 1.39 | 1.03 | 1.86 | log | |
| Number needed to treat, for one more participant with the outcome on Pembrolizumab than on Chemotherapy (SOC Treatment) | 21.3 | 11.3 | 211 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Pembrolizumab | Participants received pembrolizumab 200 mg by IV infusion on Day 1 Q3W for a maximum of 35 cycles (21-day cycles) | 126 | 636 | OG000 |
| Group 2 | Chemotherapy (SOC Treatment) | Participants received carboplatin at target dose AUC 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + paclitaxel 200 mg/m\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles) OR carboplatin target dose AUC 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + pemetrexed 500 mg/m\^2 by IV infusion on Day 1 Q3W for a maximum of 6 cycles (21-day cycles). Participants with non-squamous histologies received optional additional maintenance treatment with pemetrexed 500 mg/m\^2 by IV infusion on Day 1 Q3W | 93 | 615 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)
- Description
An AE was defined as any untoward medical occurrence in a participant administered a study treatment and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the study treatment or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of study treatment, was also an AE. The number of participants who discontinued study treatment due to an AE is presented.
- Time frame
- Up to approximately 35 months
- Population
- The analysis population consisted of all participants who received ≥1 dose of study treatment.
Source ClinicalTrials.gov
Trial
- Title
Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)
- NCT number
- NCT02220894
- Phases
- PHASE3
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- pembrolizumab, carboplatin, paclitaxel, pemetrexed
- Lead sponsor
- Merck Sharp & Dohme LLC
- Results first posted
- 2019-03-15
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02220894?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02220894-4b7e0064